Breaking News Instant updates and real-time market news.

LB

Labarge

$71.81

-0.27 (-0.37%)

, GPS

Gap

$25.57

-0.61 (-2.33%)

06:20
11/28/16
11/28
06:20
11/28/16
06:20

L Brands upgraded to Neutral from Underweight at Piper Jaffray

Piper Jaffray analyst Neely Tamminga upgraded L Brands(LB) to Neutral saying the stock at current levels is already "indicating fundamental disappointment in the near-term." The analyst keeps a $67 price target for the shares. Tamminga this morning also upgraded Gap (GPS) to Neutral.

LB

Labarge

$71.81

-0.27 (-0.37%)

GPS

Gap

$25.57

-0.61 (-2.33%)

  • 29

    Nov

  • 09

    Jan

LB Labarge
$71.81

-0.27 (-0.37%)

11/07/16
11/07/16
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. BioMarin (BMRN) downgraded to Neutral from Overweight at Piper Jaffray with analyst Joshua Schimmer saying he sees a "number of under-appreciated" risks ahead. 2. Akorn (AKRX) downgraded to Underperform from Buy at BofA/Merrill and to Hold from Buy at WallachBeth. 3. GoPro (GPRO) downgraded to Underperform from Neutral at BofA/Merrill. 4. L Brands (LB) downgraded to Underperform from Hold at Jefferies with analyst Randal Konik citing rising competition and pricing competition. 5. Xerox (XRX) downgraded to Underweight from Equal Weight at Morgan Stanley with analyst Brian Essex saying both the BPO and DocTech businesses are facing secular pressures and said the Conduent spinco will add $2B of net incremental leverage and faces headwinds in both growth and pricing and will need to focus on margin expansion to drive shareholder value. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, cllick here.
11/14/16
SBSH
11/14/16
UPGRADE
SBSH
Buy
L Brands upgraded to Buy from Neutral at Citi
Citi analyst Paul Lejuez upgraded L Brands to Buy citing his more bullish view of Specialty Retail and Department Stores. The likelihood of tax reform under a President Trump should put more money in the pockets of consumers, Lejuez tells investors in a research note.
11/14/16
11/14/16
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Lockheed Martin (LMT) upgraded to Buy from Hold at Stifel with analyst Joseph DeNardi saying he is pleased with the company's comments regarding its 2018 free cash flow outlook, and he thinks that it could benefit from increased defense spending in the wake of the election results. 2. Philip Morris (PM) upgraded to Buy from Outperform at CLSA with analyst Michael Levy citing the recent pullback for his rating change and said he sees the company adding to its buyback. 3. Citi (C) upgraded to Overweight from Equal Weight at Morgan Stanley with analysts led by Betsy Graseck saying the Republican sweep is positive for all financial stocks due to increased growth, higher rates, lower taxes, and less regulation. 4. U.S. Steel (X) and AK Steel (AKS) upgraded to Overweight from Equal Weight at Morgan Stanley. 5. L Brands (LB), Kohl's (KSS), and Chico's(CHS) were upgraded to Buy from Neutral at Citi, while Chico's was also upgraded to Outperform from Peer Perform at Wolfe Research. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
11/18/16
SBSH
11/18/16
NO CHANGE
Target $84
SBSH
Buy
Citi names L Brands a new top pick
After upgrading the shares this week, Citi analyst Paul Lejuez names L Brands his new top pick among Specialty Softline Retailers. The bad news is out following the company's lowered Q4 guidance, and investors should start to look toward an inflection in the second half of 2017, Lejuez tells investors in a research note. He has a Buy rating on L Brands with an $84 price target.
GPS Gap
$25.57

-0.61 (-2.33%)

11/18/16
JEFF
11/18/16
NO CHANGE
Target $36
JEFF
Buy
Gap price target raised to $36 from $32 at Jefferies
Jefferies analyst Randal Konik raised his price target for Gap to $36 saying the retailer's Q3 results point to a bottoming in fundamentals. The analyst views the Q4 guidance as conservative and expects Gap's "gradual improvement" to continue. He reiterates a Buy rating on the shares. Citi this morning downgraded Gap to Sell.
11/18/16
BARD
11/18/16
NO CHANGE
Target $28
BARD
Neutral
Gap risk/reward balanced at current levels, says Baird
Baird analyst Mark Altschwager noted Gap's Q3 results were mixed, as the company reported in-line earnings but a big gross margins beat. The analyst said the gross margins beat was due to one-time factors and that cautious guidance suggested a Q4 retrenchment in margins. With its recent share price appreciation, Altschwager feels the risk/reward is balanced. Altschwager maintained his Neutral rating and $28 price target on Gap shares.
11/18/16
11/18/16
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Wells Fargo (WFC) downgraded to Underperform from Market Perform at BMO Capital with analyst James Fotheringham saying that the shares don't reflect the impact of its "recent cross-selling issues." 2. Gap (GPS) downgraded to Sell from Neutral at Citi with analyst Paul Lejuez citing expectations that the company's brands will continue to struggle. 3. Citi (C) downgraded to Neutral from Outperform at Macquarie with analyst David Konrad saying investors should shift exposure to names that have more leverage to capital markets and increased economic activity and away from global banks. 4. Torchmark (TMK) downgraded to Underperform from Neutral at BofA/Merrill with analyst Seth Weiss citing relative valuation. 5. First Solar (FSLR) downgraded to Sell from Neutral at UBS with analyst Julien Dumoulin-Smith saying the recently issued 2017 guidance "is not the trough in expectations." This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
11/28/16
PIPR
11/28/16
UPGRADE
Target $23
PIPR
Neutral
Gap upgraded to Neutral from Underweight at Piper Jaffray
Piper Jaffray analyst Neely Tamminga upgraded Gap to Neutral saying the shares, are dropping 17% since the earnings report, are appropriately reflecting concerns on fundamentals. The analyst keeps a $23 price target for the stock.

TODAY'S FREE FLY STORIES

TLLP

Tesoro Logistics

$48.63

0.92 (1.93%)

07:09
12/06/16
12/06
07:09
12/06/16
07:09
Conference/Events
Tesoro Logistics to host analyst and investor day »

Analyst and Investor Day…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

  • 06

    Dec

MIK

Michaels

$24.31

0.34 (1.42%)

07:08
12/06/16
12/06
07:08
12/06/16
07:08
Earnings
Michaels sees Q4 adjusted EPS 94c-98c, consensus 99c »

For the fourth quarter of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

MMLP

Martin Midstream Partners

$16.15

-0.3 (-1.82%)

07:08
12/06/16
12/06
07:08
12/06/16
07:08
Upgrade
Martin Midstream Partners rating change  »

Martin Midstream Partners…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

MIK

Michaels

$24.31

0.34 (1.42%)

07:08
12/06/16
12/06
07:08
12/06/16
07:08
Earnings
Michaels reports Q3 adjusted EPS 40c, consensus 43c »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

IMMU

Immunomedics

$3.28

0.04 (1.23%)

07:08
12/06/16
12/06
07:08
12/06/16
07:08
Hot Stocks
Immunomedics introduces new ADC at ASH 2016 »

Immunomedics announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

  • 14

    Dec

  • 16

    Feb

SAGE

SAGE Therapeutics

$51.82

2.8 (5.71%)

07:07
12/06/16
12/06
07:07
12/06/16
07:07
Hot Stocks
SAGE Therapeutics announces expedited SAGE-547 development in PPD treatment »

Sage Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Dec

SCSS

Select Comfort

$22.96

0.64 (2.87%)

07:07
12/06/16
12/06
07:07
12/06/16
07:07
Downgrade
Select Comfort rating change  »

Select Comfort downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MIK

Michaels

$24.31

0.34 (1.42%)

07:07
12/06/16
12/06
07:07
12/06/16
07:07
Hot Stocks
Michaels announces increase of share repurchase program by $300M »

In December 2016, the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

PFG

Principal Financial

$59.47

1.69 (2.92%)

07:06
12/06/16
12/06
07:06
12/06/16
07:06
Conference/Events
Principal Financial to host conference call »

Conference call to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

SPPI

Spectrum

$4.03

0.03 (0.75%)

07:06
12/06/16
12/06
07:06
12/06/16
07:06
Hot Stocks
Spectrum highlights survival advantage in case match control analysis of PROPEL »

Spectrum Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

  • 11

    Dec

PLUG

Plug Power

$1.47

0.04 (2.80%)

07:06
12/06/16
12/06
07:06
12/06/16
07:06
Initiation
Plug Power initiated  »

Plug Power initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

PSTI

Pluristem

$1.55

0.08 (5.44%)

07:06
12/06/16
12/06
07:06
12/06/16
07:06
Hot Stocks
Pluristem PLX-R18 advances into second cohort of study for ARS »

Pluristem Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GPP

Green Plains Partners

$17.85

-0.15 (-0.83%)

07:06
12/06/16
12/06
07:06
12/06/16
07:06
Upgrade
Green Plains Partners rating change  »

Green Plains Partners…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AZN

AstraZeneca

$25.82

-0.07 (-0.27%)

07:05
12/06/16
12/06
07:05
12/06/16
07:05
Hot Stocks
AstraZeneca says data presented shows TAGRISSO superiority over chemotherapy »

AstraZeneca presented…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

  • 16

    Feb

EARS

Auris Medical

07:05
12/06/16
12/06
07:05
12/06/16
07:05
Hot Stocks
Auris Medical on track to resume enrollment of Keyzilen Phase 3 trial »

Auris Medical Holding…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SNCR

Synchronoss

$49.00

1.81 (3.84%)

, IL

Intralinks

$11.27

0.11 (0.99%)

07:04
12/06/16
12/06
07:04
12/06/16
07:04
Earnings
Synchronoss sees FY17 pro forma EPS $2.45-$2.60 for combined entity »

May not compare to…

SNCR

Synchronoss

$49.00

1.81 (3.84%)

IL

Intralinks

$11.27

0.11 (0.99%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 12

    Dec

  • 13

    Dec

CHTR

Charter

$270.93

4.26 (1.60%)

07:04
12/06/16
12/06
07:04
12/06/16
07:04
Initiation
Charter initiated  »

Charter initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

MDGN

Medgenics

07:04
12/06/16
12/06
07:04
12/06/16
07:04
Initiation
Medgenics initiated  »

Medgenics initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

AM

Antero Midstream

$28.48

-0.1 (-0.35%)

07:04
12/06/16
12/06
07:04
12/06/16
07:04
Upgrade
Antero Midstream rating change  »

Antero Midstream upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HSBC

HSBC

$39.86

0.17 (0.43%)

07:03
12/06/16
12/06
07:03
12/06/16
07:03
Upgrade
HSBC rating change  »

HSBC upgraded to Equal…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TGTX

TG Therapeutics

$5.70

0.2 (3.64%)

07:03
12/06/16
12/06
07:03
12/06/16
07:03
Hot Stocks
TG Therapeutics GENUINE Phase 3 study reaches target enrollment »

TG Therapeutics announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SNCR

Synchronoss

$49.00

1.81 (3.84%)

07:03
12/06/16
12/06
07:03
12/06/16
07:03
Hot Stocks
Synchronoss to divest part of activation business to Sequential for $146M »

Synchronoss is also…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

  • 13

    Dec

SNCR

Synchronoss

$49.00

1.81 (3.84%)

, IL

Intralinks

$11.27

0.11 (0.99%)

07:03
12/06/16
12/06
07:03
12/06/16
07:03
Hot Stocks
Synchronoss to acquire Intralinks for $13/share, or $821M in equity value »

Synchronoss Technologies…

SNCR

Synchronoss

$49.00

1.81 (3.84%)

IL

Intralinks

$11.27

0.11 (0.99%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 12

    Dec

  • 13

    Dec

TEVA

Teva

$37.04

0.51 (1.40%)

07:02
12/06/16
12/06
07:02
12/06/16
07:02
Recommendations
Teva analyst commentary  »

Wells views departure of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Apr

NVCN

Neovasc

$1.42

0.56 (65.12%)

07:02
12/06/16
12/06
07:02
12/06/16
07:02
Hot Stocks
Neovasc provides update on Tiara transcatheter mitral valve »

Neovasc provided an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.